Biotech Watch List: Omeros Corporation (NASDAQ:OMER), Alder Biopharmaceuticals Inc (NASDAQ:ALDR), Corium International Inc (NASDAQ:CORI), Ardelyx Inc (NASDAQ:ARDX)

Omeros Corporation (NASDAQ: OMER) announced that the U.S. Food and Drug Administration (FDA) has approved Omidria™ (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative pain. The approval comes with no post-marketing commitments other than the previously agreed study of Omidria for use in pediatric patients, which, if successfully completed, makes the drug eligible for an additional six months of marketing exclusivity in the U.S. Omeros Corporation (NASDAQ:OMER) weekly performance is 8.32%. On last trading day company shares ended up $15.36. Analysts mean target price for the company is $32.80. Omeros Corporation (NASDAQ:OMER) distance from 50-day simple moving average is 25.71%.

Alder BioPharmaceuticals, Inc. (“Alder”) (ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today provided recent corporate highlights and reported its financial results for the first quarter ended March 31, 2014. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) shares advanced 5.20% in last trading session and ended the day on $18.83. ALDR its return on assets is -121.60%.

Corium International (NASDAQ:CORI) last released its earnings data on Wednesday, May 14th. The company reported ($0.24) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.18) by $0.06. Analysts expect that Corium International will post $-0.82 EPS for the current fiscal year. Corium International Inc (NASDAQ:CORI) shares moved up 9.70% in last trading session and was closed at $7.24, while trading in range of $6.91-$7.25. Corium International Inc (NASDAQ:CORI) year to date performance is -9.50%.

Ardelyx Inc (NASDAQ:ARDX) a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, announced the pricing of its initial public offering of 4,286,000 shares of common stock at a public offering price of $14.00 per share. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol “ARDX” on June 19, 2014. In addition, Ardelyx has granted the underwriters a 30-day option to purchase up to an additional 642,900 shares of common stock at the initial public offering price to cover over-allotments, if any. The offering is expected to close on June 24, 2014 subject to customary closing conditions. Ardelyx Inc (NASDAQ:ARDX) ended the last trading day at $15.15.